Brokerages predict that Immune Design Corp (NASDAQ:IMDZ) will report $1.20 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Immune Design Corp’s earnings, with estimates ranging from $840,000.00 to $1.55 million. Immune Design Corp reported sales of $8.21 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 85.4%. The company is scheduled to issue its next earnings results on Wednesday, November 8th.

On average, analysts expect that Immune Design Corp will report full-year sales of $1.20 million for the current fiscal year, with estimates ranging from $8.26 million to $11.00 million. For the next fiscal year, analysts forecast that the company will post sales of $14.12 million per share, with estimates ranging from $9.29 million to $18.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Immune Design Corp.

Immune Design Corp (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp had a negative net margin of 1,899.31% and a negative return on equity of 70.03%. The business had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million.

IMDZ has been the topic of several recent research reports. Zacks Investment Research upgraded Immune Design Corp from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, July 18th. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Immune Design Corp in a report on Friday, May 19th. ValuEngine upgraded Immune Design Corp from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub cut Immune Design Corp from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Finally, Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp in a report on Tuesday, June 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Immune Design Corp has a consensus rating of “Buy” and a consensus price target of $14.50.

In other Immune Design Corp news, Director Lewis W. Coleman bought 12,000 shares of Immune Design Corp stock in a transaction on Tuesday, July 11th. The stock was acquired at an average price of $9.05 per share, with a total value of $108,600.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at $362,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Wayne Gombotz sold 10,000 shares of Immune Design Corp stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total value of $114,300.00. Following the completion of the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at approximately $377,807.22. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 30,000 shares of company stock valued at $272,760. 42.90% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Immune Design Corp by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp during the second quarter valued at approximately $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp during the second quarter valued at approximately $118,000. Trexquant Investment LP purchased a new stake in shares of Immune Design Corp during the first quarter valued at approximately $183,000. Finally, Rhumbline Advisers raised its stake in shares of Immune Design Corp by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 6,896 shares during the last quarter. 50.61% of the stock is owned by institutional investors and hedge funds.

Shares of Immune Design Corp (NASDAQ:IMDZ) traded down 2.76% during midday trading on Friday, hitting $8.80. 116,653 shares of the stock traded hands. Immune Design Corp has a 1-year low of $4.50 and a 1-year high of $13.05. The stock has a 50 day moving average of $9.97 and a 200 day moving average of $7.22. The company’s market capitalization is $225.45 million.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Immune Design Corp (IMDZ) Will Announce Quarterly Sales of $1.20 Million” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/11/zacks-analysts-anticipate-immune-design-corp-imdz-will-announce-quarterly-sales-of-1-20-million.html.

Immune Design Corp Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.